Department of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Front Immunol. 2023 May 15;14:1165769. doi: 10.3389/fimmu.2023.1165769. eCollection 2023.
Immune imprinting is a phenomenon in which a person's immune system develops a specific immunological memory of the pathogen or vaccine due to a previous exposure. This memory basically leads to a faster and stronger immune response in a subsequent contact to the same pathogen or vaccine. However, what happens if the pathogen has changed considerably in the meantime due to mutations in the main target region of antibodies, as in the evolution of SARS-CoV-2 from the ancestral strain to B.1.1.529 (Omicron)? In this case, does immune imprinting also confer an advantage in repeated contact and does it lead to a stronger immune response?
To clarify these questions, we investigated the effects of immune imprinting in the context of SARS-CoV-2 by comparing a group of previously infection-naïve versus imprinted study participants and determined differences in humoral and cellular immune responses during and after infection with strain SARS-CoV-2 B.1.1.529 BA.1 and BA.2, respectively. We used a commercial CLIA, immunoblots, IFN-γ ELISpots and a plaque-reduction neutralization test to generate a clear and comparable picture of the humoral and cellular immune response in the two study groups.
Imprinted participants developed significantly higher antibody titers and showed significantly stronger neutralization capacity against the ancestral strain, BA.1 and BA.5. The immune response of naïve study participants was narrower and related mainly to the receptor-binding domain, which resulted in a lower neutralization capacity against other strains including BA.5. Naïve study participants showed a significantly higher cellular immune response than the imprinted study group, indicating a higher antigenic challenge. The cellular immune response was directed against general structures of SARS-CoV-2 and not specifically against the receptor-binding domain.
Viral variant infection elicits variant-specific antibodies and prior mRNA vaccination or infection with a previous SARS-CoV-2 variant imprints serological responses toward the ancestral strain rather than variant antigens. On the other hand, our study shows that the initially higher specific antibody titers due to former imprinting via vaccination or prior infection significantly increased the humoral immune response, and therefore outperformed the humoral immune response of naïve study participants.
免疫印迹是一种现象,即由于先前接触,人体的免疫系统对病原体或疫苗产生特定的免疫记忆。这种记忆基本上会导致在随后接触到相同的病原体或疫苗时产生更快、更强的免疫反应。然而,如果在此期间由于抗体主要靶区的突变,病原体发生了相当大的变化,就像 SARS-CoV-2 从原始株演变为 B.1.1.529(奥密克戎)一样,会发生什么情况?在这种情况下,免疫印迹是否也能在反复接触中带来优势,是否会导致更强的免疫反应?
为了澄清这些问题,我们通过比较一组先前未感染过的免疫印迹研究参与者和感染过 SARS-CoV-2 的研究参与者,研究了 SARS-CoV-2 背景下免疫印迹的影响,并分别确定了在感染 B.1.1.529 BA.1 和 BA.2 期间和之后体液和细胞免疫反应的差异。我们使用商业 CLIA、免疫印迹、IFN-γ ELISpot 和蚀斑减少中和试验,以生成两组研究参与者体液和细胞免疫反应的清晰且可比的图像。
免疫印迹参与者产生的抗体滴度显著更高,并显示出针对原始株、BA.1 和 BA.5 的显著更强的中和能力。未感染研究参与者的免疫反应范围较窄,主要与受体结合域相关,这导致对包括 BA.5 在内的其他菌株的中和能力较低。未感染研究参与者的细胞免疫反应显著高于免疫印迹研究组,表明抗原性挑战更高。细胞免疫反应针对 SARS-CoV-2 的一般结构,而不是针对受体结合域。
病毒变异株感染会引发针对变异株的特异性抗体,而先前的 mRNA 疫苗接种或先前感染 SARS-CoV-2 变异株会使针对原始株的血清学反应印迹,而不是针对变异株抗原。另一方面,我们的研究表明,由于先前的印迹通过接种疫苗或先前的感染产生的最初更高的特异性抗体滴度显著增加了体液免疫反应,因此优于未感染研究参与者的体液免疫反应。